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Abstract: Major adverse cardiac events, defined as death or myocardial infarction, are common
causes of perioperative mortality and major morbidity in patients undergoing non-cardiac surgery.
Reduction of perioperative cardiovascular risk in relation to non-cardiac surgery requires a stepwise
patient evaluation that integrates clinical risk factors, functional status and the estimated stress of
the planned surgical procedure. Major guidelines on preoperative cardiovascular risk assessment
recommend to establish, firstly, the risk of surgery per se (low, moderate, high) and the related
timing (elective vs. urgent/emergent), evaluate the presence of unstable cardiac conditions or a
recent coronary revascularization (percutaneous coronary intervention or coronary artery bypass
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grafting), assess the functional capacity of the patient (usually expressed in metabolic equivalents),
determine the value of non-invasive and/or invasive cardiovascular testing and then combine
these data in estimating perioperative risk for major cardiac adverse events using validated scores
(Revised Cardiac Risk Index (RCRI) or National Surgical Quality Improvement Program (NSQIP)).
This stepwise approach has the potential to guide clinicians in determining which patients could
benefit from cardiovascular therapy and/or coronary artery revascularization before non-cardiac
surgery towards decreasing the incidence of perioperative morbidity and mortality. Finally, it
should be highlighted that there is a need to implement specific strategies in the 2019 Coronavirus
disease (COVID-19) pandemic to minimize the risk of transmission of COVID-19 infection during
the preoperative risk assessment process.
Keywords: non-cardiac surgery; perioperative cardiovascular management; COVID-19; teleconsulting

1. Introduction
Cardiovascular risk of patients undergoing non-cardiac surgery results from an interplay of patient (i.e., age, comorbidities, functional capacity) and surgery-specific factors (i.e.,
type, timing and duration of surgery, duration of anesthesia) [1–5]. In European countries,
167,000 cardiovascular events occur annually in patients undergoing non-cardiac surgical
procedures, of which 19,000 are life-threatening [1–5]. Furthermore, the ongoing 2019
Coronavirus disease (COVID-19) pandemic has created new and unpredictable challenges
for modern medicine and healthcare systems, also concerning the appropriate methodology
to prevent transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
during cardiac consultation and perioperative management [6–9].
The aim of this review is to present a systematic stepwise approach to the preoperative
assessment and management of cardiovascular risk in patients undergoing non-cardiac
surgery and to discuss the related implementation during the COVID-19 pandemic based
on current scientific evidence and guidelines (Figure 1, Table 1).
Table 1. Measures to prevent SARS-CoV-2 exposure and transmission in the setting of preoperative assessment and
management of cardiovascular risk among patients undergoing non-cardiac surgery [6,7].
General Recommendations

• At the time of hospital admission, patients should undergo clinical and laboratory assessment for COVID-19 infection +
SARS-CoV-2 nucleic acid amplification testing (for example, RT-PCR) or antigen testing.
• Use “personal protective equipment” (protective masks/clothing, gloves, googles, surgical cap, etc.).
• Observe social distancing rules and routinely clean medical equipment.
• Implement teleconsulting/telemedicine whenever possible and limit number of caregivers.
• Patients should undergo SARS-CoV-2 polymerase chain reaction 48–72 h before invasive/high-risk contamination procedures
(i.e., coronary angiography, TEE, physical stress tests, etc.).
• Perform periodic COVID-19 screening of patients and caregivers (SARS-CoV-2 nucleic acid amplification testing (for example,
RT-PCR) or antigen testing.
• Check COVID-19 vaccination status for patients and caregivers.
Cardiac Imaging

• Cardiac imaging should be performed if appropriate and only if it is likely to substantially change patient management.
• A focused cardiac ultrasound study (FoCUS) is recommended to reduce the duration of exposure.
Handheld ultrasound devices should be implemented.
• The risk of contamination of equipment and personnel is very high during TEE; if necessary, consider as alternatives CCTA or
cardiac CMRI.
• CCTA may be implemented to exclude or confirm coronary heart disease.
• Avoid cardiac stress tests; if necessary, favor pharmacologic (or CCTA) to physical stress.
• If an urgent coronary angiography is needed (i.e., ACS), a dedicated COVID-19 Cath-Lab should be used.
• CMRI may be implemented in the suspicion of takotsubo syndrome or myocarditis.
ACS, acute coronary syndrome; cath lab, cardiac catheterization laboratory; CCTA, coronary computed tomographic angiography; CMRI,
cardiac magnetic resonance imaging; COVID-19, 2019 Coronavirus disease; RT-PCR, reverse transcription polymerase chain reaction;
SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TEE, transesophageal echocardiogram.

•

If an urgent coronary angiography is needed (i.e., ACS), a dedicated COVID-19 Cath-Lab should be used.
•
CMRI may be implemented in the suspicion of takotsubo syndrome or myocarditis.
ACS, acute coronary syndrome; cath lab, cardiac catheterization laboratory; CCTA, coronary computed tomographi
angiography;
cardiac
magnetic resonance imaging; COVID-19, 2019 Coronavirus disease; RT-PCR,
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transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TEE
transesophageal echocardiogram.
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undergoing non-cardiac surgery [1,2]. BNP, brain natriuretic peptides; CCTA, coronary angiography;
computed tomograph
CMR, cardiac
magnetic
resonance;
CV, cardiovascular;
electrocardiogram;
METs,
metabolic
equivalents; NT-proBNP,
angiography;
CMR,
cardiac
magnetic
resonance;ECG,
CV,
cardiovascular;
ECG,
electrocardiogram;
METs, metaboli
N-terminal prohormone of brain natriuretic peptides; OMT, optimal medical therapy; RCSI, revised cardiac index score; TTE,
equivalents; NT-proBNP, N-terminal prohormone of brain natriuretic peptides; OMT, optimal medical therapy; RCS
transthoracic echocardiography*. Handheld echocardiography +/− comprehensive TTE ** SPECT, stress echocardiography,
revised cardiac index score; TTE, transthoracic echocardiography*. Handheld echocardiography +/- comprehensive TT
stress CMR.
** SPECT, stress echocardiography, stress CMR.
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2. Step 1: Consider the Timing of Surgery
According to intervention timing, surgery can be classified into three main categories:
emergent (to be performed within 6 h), urgent (to be performed within 6–24 h) and elective (to be performed within days or even planned) [1–5]. In urgent/emergent surgeries,
the role of the cardiology consultant is to provide recommendations on perioperative
medical management, minimization of the cardiovascular risks and surveillance for cardiovascular events, usually without performing additional tests to avoid any delay in the
surgery [1–5]. Conversely, in elective procedures, a comprehensive clinical assessment of
the patient is required (including non-invasive and/or invasive testing if needed) in order
to define the overall surgical cardiovascular risk and implement appropriate therapeutic
interventions [1–5].
3. Step 2: Identify Unstable Cardiac Conditions and Recent Coronary Revascularization
3.1. Unstable Cardiac Conditions
Patients undergoing elective surgery should be carefully assessed in order to exclude
the presence of unstable cardiac conditions, namely acute coronary syndrome, acute
decompensated heart failure (HF), tachyarrhythmias or bradyarrhythmias associated with
hypotension or requiring urgent medical attention (i.e., ventricular tachycardia or highgrade atrioventricular block) and symptomatic severe valvular disease [1,2]. In this case, the
surgery should be delayed in order to evaluate and to treat the patient as appropriate [1,2].
3.2. Recent Coronary Stent Implantation
A recent coronary stent implantation needs to be ruled out considering that a premature cessation of dual antiplatelet therapy (DAPT) is associated with a high risk for
ischemic events [10–12]. In fact, a minimum period of DAPT after percutaneous coronary intervention (PCI) is required in order to allow vascular healing and progressive
stent endothelialization and, consequently, to prevent stent-related thrombotic complications [10–13]. Based on this assumption, Rossini et al. suggest that elective surgery
requiring discontinuation of the P2Y12 inhibitor be delayed at least 1 month after bare
metal stent (BMS) implantation and 3 months after drug eluting stent (DES) implantation [13]. In the case of not deferrable surgery, a multidisciplinary consultation should be
implemented in order to appropriately guide the clinical decision-making process [2,13].
As opposed to this, asymptomatic patients who underwent CABG within the previous six
years are relatively protected from myocardial infarction complicating non-cardiac surgery
and may undergo non-cardiac surgery without routine preoperative stress testing [1].
4. Step 3: Assess the Functional Capacity and the Cardiovascular Perioperative Risk
After excluding unstable cardiac conditions and recent coronary stent implantation,
patient’s functional capacity and cardiovascular perioperative risk need to be assessed. In
this regard, specific available tools may be implemented such as the Revised Cardiac Risk
Index (RCRI) and the National Surgical Quality Improvement Program (NSQIP) universal
surgical risk calculator [1,14,15].
4.1. Functional Capacity
Functional capacity, commonly measured in metabolic equivalents (METs), represents
a pivotal step of the preoperative cardiac risk assessment algorithm [1–4]. It should be
underscored that, among patients with overt cardiorespiratory disease as well as apparently
healthy subjects, functional capacity has been demonstrated to be a stronger predictor of
an increased risk of death as compared with associated clinical features or risk factors
(hypertension, smoking and diabetes) or other exercise-test indices (ST-segment depression,
peak heart rate and the development of arrhythmias during exercise) [16–18] (Table 2).
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Table 2. Assessment of functional capacity [18].
Activities

Wheight (METs)

• Can you take care of yourself (eating, dressing, bathing or using the toilet)?
• Can you walk indoors, such as around your house?
• Can you walk a block or two on level ground?
• Can you climb a flight of stairs or walk up a hill?
• Can you run a short distance?
• Can you undertake light work around the house, such as dusting or washing dishes?
• Can you perform moderate work around the house, such as vacuuming, sweeping floors
or carrying in groceries?
• Can you perform heavy work around the house, such as scrubbing floors or lifting and
moving heavy furniture?
• Can you perform yard work, such as raking leaves, weeding or pushing a power mower?
• Can you have sexual relations?
• Can you participate in moderate recreational activities, such as golf, bowling, dancing,
doubles tennis or throwing a baseball or football?
• Can you participate in strenuous sports, such as swimming, singles tennis, football,
basketball or skiing?

2.75
1.75
2.75
5.50
8.00
2.70
3.50
8.00
4.50
5.25
6.00
7.50

METs, metabolic equivalents.

4.2. Cardiovascular Perioperative Risk Scores
Perioperative major adverse cardiac events (MACEs) may be accurately predicted by
cardiovascular risk scores, namely the RCRI and the NSQIP [14,15]. The RCRI, the simplest
and most clinically used score, includes six variables (1 point is assigned to each variable):
history of ischemic heart disease, history of cerebrovascular disease, history of congestive
HF, preoperative treatment with insulin, preoperative serum creatinine level ≥ 2 mg/dL
and high-risk procedure [14].
A detailed classification of surgical interventions according to surgical risk (low,
intermediate or high) is reported in Supplementary Table S1.
The NSQIP may provide superior predictive discrimination, but it results to be more
complicated to be implemented [15].
4.3. Combining Functional Capacity and Cardiovascular Perioperative Risk Score
Combining functional capacity and cardiovascular perioperative risk score represents
a decision-making crossroad of the perioperative management pathway [1–4]. In asymptomatic patients with moderate or good functional capacity (RCRI = 0 and ≥4 METs),
additional tests are unlikely to change perioperative management. Thus, it is appropriate
to directly refer the patient for surgery. On the other hand, in patients with low (≤4 METs)
or not assessable functional capacity and/or RCRI ≥1, additional tests are advisable
(Figure 1).
5. Step 4: Measuring Blood Biomarkers Levels and Performing Electrocardiogram/
Cardiac Imaging Tests
Serum biomarkers, electrocardiogram (ECG) and non-invasive imaging cardiac tests
may represent an important added diagnostic/prognostic value in the evaluation of patients with RCRI ≥ 1 and/or <4 METs [1–3]. It should be underscored that to decrease
the risk of patient to patient, patient to imager and imager to patient SARS-CoV-2 contamination, the indication for any cardiac imaging test should be carefully evaluated [6,7,9]
(Table 1).
5.1. Biomarkers: BNP/NT-ProBNP and Troponin
The 2016 ‘Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk
Assessment and Management for Patients Who Undergo Noncardiac Surgery’ recommend
measuring brain natriuretic peptide (BNP) or the N-terminal (NT)-pro hormone BNP (NTproBNP) (to be preferred in patients taking sacubitril-valsartan) levels before surgery to
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enhance perioperative cardiac risk stratification in patients with elevated risk (i.e., patients
who are 65 years of age or older as well as in patients who are 45–64 years of age with a
RCRI score ≥ 1) [3,19].
In addition, daily troponin measurements along with ECG are currently indicated
for 48–72 h after surgery among patients with overt/suspected coronary artery disease
(CAD) and/or abnormal preoperative natriuretic peptide values (BNP > 92 ng/L or
NT-pro BNP > 300 ng/L) [3,20].
5.2. ECG
Routine preoperative resting ECG needs to be performed among patients with an
RCRI score ≥ 1 or low functional capacity (<4 METs) [1,2]. The cardiology consultant may
also consider performing ECG in patients with overt cardiovascular risk factors and/or
diseases undergoing low-risk surgery presenting [1,2].
In this regard, ECG signs of potential underlying heart disease [i.e., arrhythmias such
as atrial fibrillation (AF)/flutter and premature ventricular complexes, left ventricular hypertrophy, left bundle branch block and ischemic alterations] should be carefully searched
and interpreted in the light of patients’ clinical features [1,2].
5.3. Resting Transthoracic Color-Doppler Echocardiography
Resting transthoracic color-Doppler echocardiography (TTE) is the most readily available and versatile tool for evaluating heart structure and function [21]. It should be
underlined that routine TTE is not indicated during the preoperative cardiovascular assessment [1,2]. However, it may be useful in patients with intermediate/high surgical risk
(RCRS ≥ 1) and/or with poor functional capacity (<4 METs) [1,2]. Due to the COVID-19
pandemic it is safe to undertake a bedside quick focused cardiac ultrasound study (FoCUS)
according to standardized but restricted clinically driven protocol in order to reduce patient contact with the machine as well as with the clinician performing the test [6,7,9]. In
this regard, handheld ultrasound devices are being increasingly used in clinical practice
today [6,9,22] (Table 1).
5.4. Non-Invasive Imaging Stress Testing for Ischemic Heart Disease
Non-invasive cardiac imaging stress testing (stress echocardiography, gated singlephoton emission computed tomography (SPECT) and stress cardiac magnetic resonance
imaging (CMRI)) is usually implemented among patients with poor functional capacity
(<4 METs) candidate to intermediate-high risk non-cardiac surgery (RCRI ≥ 1) in order to
detect the presence and to define the extent of stress-inducible ischaemia [1–4]. A negative
test is associated with low incidence of perioperative cardiac events (high negative but low
positive predictive value (between 25 and 45%)) [1–4]. The type of stress testing used should
be chosen by the patient’s clinical characteristics along with local availability and expertise.
Virtually all patients who are anticipated to reach a satisfactory workload should undergo
an exercise stress test (treadmill, recumbent bicycle) rather than a pharmacologic stress
test (vasodilators such as dipyridamole and adenosine or inotropes as dobutamine) [1,2,5].
It has to be emphasized that the performance of exercise testing has major limitations
in the SARS-CoV-2 pandemic as during exercise there is “de facto” a higher exposition
to COVID-19 as a direct consequence of the increased patient breath rate along with the
amount of aerosol or droplet production [6,7]. In this regard, pharmacologic rather than
physical stress should be preferred. Coronary computed tomographic angiography (CCTA)
remains an additional option to be considered [6,7].
5.5. Coronary Angiography
Indications for preoperative conventional coronary angiography (CA) are confined to a
highly selected patient cohort and reflect those in the non-surgical setting [1–4,11,12,23,24].
Specifically, the 2014 ‘’ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management’ recommend CA in unstable patients scheduled for elective surgery
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(class of recommendation I A) [1]. CA should also be performed in unstable patients
scheduled for urgent surgery (class of recommendation IIa C). Furthermore, it has to be
underscored that in selected stable patients (RCRI ≥ 1 and/or ≤4 METS) CA is usually preceded and triggered by an imaging stress test positive for moderate/severe ischemia [1,2]
(Figure 1). However, the decision to proceed to CA is up to a multidisciplinary consensus
among cardiologists, anesthesiologists and surgeons, taking into account the single patient
based comprehensive clinical scenario.
5.6. Coronary Computed Tomographic Angiography
CCTA prior to non-cardiac surgery remains uncertain. [1] However, CCTA reducing the potential COVID-19 exposure time between health care personnel and patients
may be preferred over CA or even other non-invasive imaging modalities to assess CAD
severity [7].
However, in every day clinical practice, most patients undergoing major non-cardiac
surgery have to perform a contrast enhanced CT exam for vascular assessment (i.e., CT
angiography) and/or for oncologic purposes (i.e., staging, restaging and so forth). With
currently available state-of-the-art CT technology it really does not make a big difference to
include a proper CCTA within a contrast enhanced CT performed for other reasons. It does
not require a significant increase in radiation exposure or contrast material administration.
Of course, this is a very demanding proposition under technical and logistical aspects. We
would call this an “opportunistic” application of CCTA for risk stratification (Figure 1).
This is not just an additional exam, but it is the actual improvement of cardiovascular risk
stratification in patients undergoing surgery and high-risk procedures. There should be
a careful evaluation of patients who would not adequately benefit from this assessment.
On the other hand, the technological development of current and next generation CT
equipment will progressively make it more and more easy to obtain this kind of information.
At some point in time, the adequate visualization of heart and coronary arteries will become
just “collateral” information already included in the CT package. Of course, this will
completely change the way we look at our patients. In addition, the potential to guide the
pharmacological management of these patients during and after the procedure is quite
relevant [25].
5.7. Cardiac Magnetic Resonance Imaging
Stress CMRI can be employed for risk stratification to assess myocardial ischemia
through the injection of the gadolinium contrast agent at rest and after administration of
a pharmacological stressing agent, either positive inotropic/chronotropic or vasodilator
agents [26] (Figure 1). Reduced blood supply at rest is seen in patients with myocardial
ischemia or fibrosis while impaired first pass of the contrast agent performed during
pharmacological stress could detect flow-limiting coronary artery stenosis [27]. In addition,
amongst cardiac masses, low blood supply could help to discriminate mural thrombi
from other masses [26]. Lastly, due to its accuracy and reproducibility, CMRI could
provide reliable information on cardiac morphology and masses, global and regional
cardiac function and on myocardial viability through the peripheral venous injection of the
gadolinium-based contrast agent [26,27].
6. Perioperative Management of Cardiovascular Medications
Cardiovascular medications should be patient tailored considering clinical characteristics and surgical risk [2]. As a general rule, cardiovascular medications, if appropriate,
effective and not contraindicated, can be continued through surgery [2]. On the other hand,
in naïve patients, specific therapy needs to be started at least 2–3 weeks before surgery in
order to select appropriate drug dose titration [2]. Particular attention should be paid to
the antithrombotic treatment balancing bleeding vs. thrombotic risk [1,2,13,28,29].
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6.1. Beta-Blockers
Beta-blockers antagonize the effect of beta-adrenergic stimuli reducing heart rate,
contractility, atrioventricular conduction and myocardial oxygen demand. Furthermore, by
prolonging the diastolic period, beta-blockers may increase the perfusion of ischemic areas
[19, 11, 12, 24]. Thus, given the proven beneficial effects in specific cardiac diseases, namely
ischemic heart diseases and chronic HF, it is wise to implement, if not contraindicated, betablocker therapy among selected patients with the recommendation to initiate 1–2 weeks
prior to surgery in order to test tolerability and safety [1,2,4,11,12,19,30–32].
6.2. Statins
Statins are potent inhibitors of cholesterol biosynthesis with “pleiotropic” effects such
as improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation and inhibiting the thrombogenic response [33].
The 2014 ‘ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery’ suggest initiation of statins is appropriate
in patients with indications for lipid-lowering therapy and in those scheduled for vascular
surgery [2,4,33].
6.3. ACEI-ARBs and Other Drugs
Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers
(ARBs), sacubitril-valsartan, calcium channel blockers, alfa2 agonists, nitrates and diuretics
follow general rules indicating they should be continued in patients currently receiving these medications but be cautious starting them 2–3 weeks before surgery, carefully
monitoring blood pressure, electrolytes and renal function [1–5].
7. Perioperative Management of Antithrombotic Therapy
In patients scheduled for elective non-cardiac surgery, it is mandatory to comprehensively assess the patient’s atherothrombotic/bleeding risk in order to choose the
most suitable perioperative approach regarding antiplatelet and/or anticoagulant therapy [1,2,13,29].
7.1. Antiplatelet Therapy
Aspirin
Aspirin (ASA), oral irreversible of cyclooxygenase 1 inhibitor, does not need to be
discontinued in patients currently taking this medication as secondary prevention except
in very high bleeding risk surgery such as transurethral resection of the prostate (TURP),
neurosurgery or posterior chamber of the eye ophthalmological interventions [2,13]. If
this is the case, it does need to be stopped 5 days before surgery. However, it may be
resumed 24–72 h after surgery depending on the patient’s hemostasis state [2,13]. As a note,
ASA should not be initiated before surgery in naïve patients [1]. It should be highlighted
continuation of low dose aspirin decreases the stent thrombosis risk even when clopidogrel,
prasugrel or ticagrelor are discontinued in perioperative period [1,2].
7.2. Dual Antiplatelet Therapy
Given the synergistic importance of the adenosine diphosphate P2Y12 and the thromboxane pathways in amplifying platelet activation, DAPT, aspirin in combination with
a P2Y12 inhibitors (clopidogrel, prasugrel and ticagrelor) is the cornerstone of treatment
after coronary stent implantation [11,12,34].
When approaching perioperative management of antithrombotic therapy in patients
treated with coronary stents undergoing non-cardiac surgical interventions it is crucial to define the thrombotic risk of the patient vs. the bleeding risk of the procedure
(Supplementary Table S2) [2,13]. It should be pointed out the thrombotic risk of the patient
results from the interplay of multiple factors: patient clinical characteristics (i.e., history of
CAD along with the presence of co-morbidities such as diabetes, renal dysfunction, chronic
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HF, peripheral artery diseases), coronary anatomy status (multiple/long bifurcation lesions,
small vessels, left main involvement), type (BMS, DES, bioresorbable vascular scaffold),
size and number of stents implanted, time interval from PCI to surgery along with potential
adverse events of early DAPT cessation [13,35].
However, it is advisable to use the “Stent and Surgery app” (https://itunes.apple.
com/us/app/stent-surgery/id551350096?mt.8) in order to rapidly and objectively assess
the thrombotic risk of the patient vs. the hemorrhagic risk of the surgery and, consequently,
choose the most appropriate management [13] (Table 3).
Table 3. Websites/Apps of interest [1–4,6,7,29].
Ref/Web-Sites/Apps

Link

2014 ‘ESC/ESA Guidelines on non-cardiac surgery:
Cardiovascular assessment and management’.

https://www.escardio.org/Guidelines/Clinical-PracticeGuidelines/ESC-ESA-Guidelines-on-non-cardiac-surgerycardiovascular-assessment-and-managem

‘ACC/AHA Guideline on Perioperative Cardiovascular
Evaluation and Management of Patients Undergoing
Noncardiac Surgery’.

https://www.ahajournals.org/doi/pdf/10.1161/CIR.000000
0000000106

‘CCS Guidelines on Perioperative Cardiac Risk Assessment and
Management for Patients Who Undergo Noncardiac Surgery’.

https://www.onlinecjc.ca/article/S0828-282X(16)30980-1/pdf

2021 ‘EHRA Practical Guide on the Use of Non-Vitamin K
Antagonist Oral Anticoagulants in Patients with
Atrial Fibrillation’.

https://www.escardio.org/Guidelines/RecommendedReading/Heart-Rhythm/Novel-Oral-Anticoagulants-forAtrial-Fibrillation

‘ESC Guidance for the Diagnosis and Management of CV
Disease during the COVID-19 Pandemic’.

https://www.escardio.org/static-file/Escardio/EducationGeneral/Topic%20pages/Covid-19/ESC%20Guidance%20
Document/ESC-Guidance-COVID-19-Pandemic.pdf

‘COVID-19 pandemic and cardiac imaging: EACVI
recommendations on precautions, indications, prioritization,
and pro-tection for patients and healthcare personnel’.

https:
//academic.oup.com/ehjcimaging/article/21/6/592/5815408

Stent and Surgery App

https://play.google.com/store/apps/details?id=com.
araneum.stentsurgery&hl=it&gl=US

MDCalc Medical Calculator App

https://play.google.com/store/apps/details?id=com.
mdaware.mdcalc&hl=it&gl=US
• ASA Physical Status/ASA Classification.
• Creatinine clearance (Cockcroft-Gault Equation).
• CHA2 DS2 -VASc Score.
• Child–Pugh Score.
• QT corrected interval (QTc).
• HAS-BLED Score.
• Revised Cardiac Risk Index.

ACC, American College of Cardiology; AHA, American Heart Association; CCS, Canadian Cardiovascular Society; EACVI, European
Association of Cardiovascular Imaging; EHRA, European Heart Rhythm Association; ESA, European Society of Anesthesiology; ESC,
European Society of Cardiology.

7.3. Intravenous Reversible Antiplatelet Agents
The reversible intravenous antiplatelet agents available for clinical use, and thus of
potential utility for bridging, include P2Y12 inhibitors such as cangrelor and glycoprotein
IIb/IIIa inhibitors (GPIIb-IIIa) such as tirofiban and eptifibatide. In this regard, while
non-deferrable surgery at low risk of bleeding can be undertaken on DAPT therapy, high
bleeding risk surgery should be deferred (if possible) among patients on DAPT deemed
at high risk for stent thrombosis. If not deferrable, bridging therapy with intravenous
reversible antiplatelet agents may be a valuable option. If this is the case, ASA should
be continued (except in the aforementioned very high bleeding risk surgery) while oral
P2Y12 inhibitors should be discontinued (clopidogrel and prasugrel 5 days before and
ticagrelor 7 days before surgery) with intravenous reversible antiplatelet agents bridging
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therapy started 2–4 days after discontinuation. Of note, cangrelor needs to be continued
until 1–6 h before surgery and GPIIb-IIIa inhibitors until 4–6 h before surgery [13,36,37].
Then, patients should resume oral P2Y12 inhibitors (clopidogrel preferred) within 24–48 h
after surgery, with loading dose [13].
7.4. Anticoagulant Therapy
The perioperative management of anticoagulant therapy remains challenging, mainly
depending on the patients clinical characteristics (age, body weight, history of gastrointestinal or intracranial bleeding, renal and hepatic function, drugs interactions), the bleeding
risk of surgery (minor, low and high risk) and the class (type) of anticoagulant used
(vitamin K antagonists (VKAs), non-vitamin K antagonist oral anticoagulants (NOACs),
heparin) [1,29].
7.4.1. Vitamin K Antagonists
VKAs are a class of oral anticoagulant drugs that act as antagonists to vitamin K. The
mechanism of action is to interfere with the interaction between vitamin K and coagulation
factors II, VII, IX and X [38].
Patients on VKAs scheduled for minor bleeding risk elective surgery (i.e., dental, cataract
or glaucoma interventions, endoscopy without biopsy or resection, minor skin surgery) do
not need to stop anticoagulant therapy. However, it is wise to keep international normalized
ratio (INR) levels in the lower therapeutic range [1]. On the other hand, patients on VKAs
scheduled for low (i.e., endoscopy with biopsy, prostate or bladder biopsy, electrophysiological
study or catheter ablation, pacemaker implantation, etc.) or high-risk (i.e., thoracic surgery,
abdominal surgery, major orthopaedic surgery, liver and kidney biopsy, polypectomy, etc.)
bleeding elective surgery do need to discontinue VKAs 3–5 days before surgery. In this regard,
surgery can be safely performed when INR is ≤1.5. However, in VKAs patients with a high
thromboembolic risk of (i.e., AF with a CHA2DS2 -VASc ≥4, mechanical prosthetic heart
valves, newly inserted biological prosthetic heart valves or mitral valvular repair (within
the past 3 months), recent venous thromboembolism (within 3 months), thrombophilia),
discontinuation of VKAs should be followed by bridging therapy with a therapeutic dose
of unfractionated heparin (UFH) or low molecular weight heparin (LMWH) [1]. VKAs can
be resumed on day 1 or 2 after surgery depending on adequate hemostasis. It should be
underlined that the use of VKAs in patients with advanced liver disease and coagulopathy is
challenging due to intrinsically elevated INR values [1] (Table 4).
7.4.2. Non-Vitamin K Antagonist Oral Anticoagulants
NOACs (Table 4) include apixaban, dabigatran, rivaroxaban and edoxaban. Apixaban,
edoxaban and rivaroxaban inhibit Factor Xa, whereas dabigatran is a direct thrombin
inhibitor [38]. All NOACs have a predictable effect (onset and offset) without need for
regular anticoagulation monitoring [38]. The ‘2021 European Heart Rhythm Association
Practical Guide on the Use of NOACs in Patients with Atrial Fibrillation’ recommends:
(a) not to interrupt NOACs before minor bleeding risk surgery that can be performed
12–24 h after the last NOACs intake [29]; (b) to take the last dose of apixaban, edoxaban
or rivaroxaban 24–36 h before low bleeding risk surgery and 24–48 h before if dabigatran
is chosen [29]; and (c) to take the last dose of apixaban, edoxaban or rivaroxaban at least
48 h before high bleeding risk surgery and 48–96 h before if dabigatran is chosen [26]. Full
dose of NOACs may be resumed 24 h post low-bleeding risk interventions and 48–72 h
post high-bleeding risk interventions depending on hemostasis state [29]. However, as
a general rule, the dose of NOACs is highly dependent on renal function along with the
patient’s age (<80 vs. ≥80 years) and weight (>60 vs. ≤60 kg) [29]. It has to be highlighted
that preoperative bridging with LMWH or UFH is not needed [29].
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Table 4. Management of VKAs and NOACs in patients undergoing non-cardiac surgery [1,29].
â Elective surgery

VKAs

• Minor bleeding risk surgery: no change in oral anticoagulation therapy is needed but keep INR levels in
the lower therapeutic range.
• Low/high bleeding risk surgery: take the last dose 3–5 days before surgery; when INR is ≤1.5, surgery can
be performed safely.
â VKAs should be resumed on day 1 or 2 after surgery depending on the patient’s hemostatic status, but no
less than 12 h after the procedure.
â If high risk of thromboembolism 1 , bridging therapy with UFH or LMWH 2 needs to be implemented.
â In case of urgent/emergent surgery, immediately discontinue. If needed, reversal with vitamin K or
fresh-frozen plasma/PCCs.
â Elective surgery

NOACs

Take the last dose before surgery according to CrCl:
• Minor bleeding risk surgery: ≥12 h or 24 h 1
• Low bleeding risk surgery:
- apixaban/edoxaban/rivaroxaban ≥24 h 2
- dabigatran ≥ 24–48 h 3
• High bleeding risk surgery:
- apixaban/edoxaban/rivaroxaban ≥48 h 4
- dabigatran ≥48–96 h 5
â No bridging with heparin required.
â In case of urgent/emergent surgery immediately discontinue. If needed, reversal with idaracizumab
(dabigatran) or PCCs or aPCCs.

aPCCs, activated prothrombin complex concentrate; CrCL, creatinine clearance; INR, international normalized ratio; LMWH, low molecular
weight heparin; NOACs, non-vitamin K antagonist oral anticoagulants; PCCs, prothrombin complex concentrate; UFH, unfractionated
heparin; VKAs, vitamin K antagonists. 1 Patients with at least one of the following: AF with a CHA2DS2-VASc score ≥ 4, mechanical
prosthetic heart valves, newly inserted biological prosthetic heart valves, mitral valvular repair (within the past 3 months), recent venous
thromboembolism (within 3 months), thrombophilia. 2 CrCl > 30 mL/min: ≥24 h; CrCl < 29 mL/min: ≥36 h; CrCl < 15 mL/min: not
indicated. 3 CrCl ≥ 80 mL/min: ≥24 h; CrCl 50–79 mL/min: ≥36 h; CrCl 30–49 mL/min: ≥48; CrCl < 29 mL/min: not indicated.
4 CrCl > 15 mL/min: ≥48 h; CrCl < 15 mL/min: not indicated. 5 CrCl ≥ 80 mL/min: ≥48 h; CrCl 50–79 mL/min: ≥72 h; CrCl 30–49
mL/min: ≥96; CrCl < 29 mL/min: not indicated.

7.4.3. Unfractionated Heparin and Low-Molecular-Weight Heparin
aPTT, Activated partial thromboplastin time; Da, Dalton; GFR, glomerular filtration
rate; HIT, heparin-induced thrombocytopenia; LMWH, low-molecular-weight heparin;
UFH, unfractionated heparin.
Heparin is a heterogeneous mixture of polysaccharide fragments with varying molecular weights: UFH and LMWH [24]. Heparin clinical use is prophylactic as well as
therapeutic [24] (Table 5).
Prophylactic use is indicated for prevention of venous thromboembolism in the case
of surgery carrying a moderate-high thrombotic risk (i.e., orthopaedic surgery or general
surgery) or in a non-surgical setting for patients who are immobilized due to acute/chronic
diseases (i.e., HF, respiratory failure, infections, etc.). In most cases, for prophylaxis, LMWH
is often used in once daily subcutaneous doses of 4000–5000 UI (or 2500 to 3000 units twice
daily). Alternatively, UFH may be given subcutaneously in fixed doses of 5000 UI two to
three times daily. It has to be underlined that prophylactic doses of LMWH as well as UFH
do not need coagulation monitoring [24].
Therapeutic use, in the preoperative setting, is indicated as “bridging therapy” in
patients who require interruption of VKAs, as discussed above. For therapeutic purposes
UFH is administered as an initial bolus of 5000 U followed by 30,000 to 35,000 U/24 h
with activated partial thromboplastin time (aPTT) or anti factor Xa level monitoring while
LMWH is used in doses of 100 U/kg twice daily (no monitoring is needed) and halved in
patients with renal impairment (Creatinine Clearance (ClCr) < 30 mL/min) [24].
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Table 5. Characteristics of unfractionated heparin (UFH) vs. low molecular weight heparin (LMWH) and their management
in patients undergoing non-cardiac surgery [1,24].
Features

UFH

LMWH

Mean molecular weight

15,000 Da

5000 Da

Target

Xa and IIa

Xa and IIa (greater Xa inhibition than IIa)

Bioavailability (%)

30

90

Half-life

1h

4h

Renal Excretion

No

Yes

Antidote (Protamine sulfate)

Complete reversal

Partial reversal (~50%)

Heparin-induced
thrombocytopenia (HIT)

<5%

<1%

Method of administration

Intravenous infusion or less frequently
subcutaneously.

Subcutaneously (less frequently can be
administered intravenously if a rapid
anticoagulant response is needed).

Monitoring

aPTT

Not necessary (predictable
anticoagulant response).

Dosages

- Usually given in fixed doses of 5000 units
subcutaneously two or three times daily. *

- 4000 to 5000 units daily or 2500 to
3000 units twice daily subcutaneously.

- Initial bolus of 5000 U followed by 30,000 to
35,000 U/24 h followed by intravenous
infusion with aPTT monitoring.

- Subcutaneously according to body weight
(100 U/kg twice daily).
- The dose needs to be reduced in patients
with renal impairment
(GFR < 30 mL/min/1.73 m2 ).

Management before
non-cardiac surgery

- Discontinue administration ≥4 h
before surgery.
- Resume full dose ≥12 h after surgery.
- In case of urgent/emergent surgery
immediately discontinue. If needed, complete
reversal with protamine sulphate.

- Discontinue administration ≥12 h
before surgery.
- Resume full dose ≥12 h after surgery.
- In case of urgent/emergent surgery
immediately discontinue. If needed, partial
reversal (~50%) with protamine sulphate.

Limitations

Dose-dependent clearance (binds to
endothelial cells); variable anticoagulant
response (binds to plasma proteins).

Potential accumulation in patients with renal
insufficiency (GFR <30 mL/min/1.73 m2 ).

Side effects

- Short term:
• bleeding (most common, increasing with
higher heparin doses or concomitant
administration of antiplatelet or
fibrinolytic agents);
• HIT (it occurs 5 to 14 days after the
initiation of heparin therapy, but it may be
manifested earlier if the patient has received
heparin within the past 3 months);
• elevated levels of transaminases (rapidly
return to normal when the drug is stopped).
- Long term:
• osteoporosis.

The same as UFH but less frequent.

• Prophylaxis
• Therapeutic

* Monitoring of coagulation is unnecessary.
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In general, due to efficacy/safety better evidence, LMWH as “bridging therapy” is
preferred to UFH except in patients with mechanical prosthetic heart valves. As a note,
UFH should be discontinued 4 h before surgery and low molecular weight heparin 12 h
before and then resumed 12 h after the procedure [1].
It should be highlighted that protamine sulphate can be utilized to neutralize heparin in
serious bleeding, most often occurring in cases of concomitant use of antiplatelet/fibrinolytic
drugs and/or recent surgery or trauma. Other side effects include, especially for UFH, heparininduced thrombocytopenia (HIT), elevated levels of transaminases and osteoporosis [24].
8. Post-Operative Major Adverse Cardiovascular Events Prevention
During the high-risk patient’s post-operative phase, it remains essential to prevent
MACEs. In this regard, the caring team should pay attention to pain, oxygenation and
hemodynamics control. Levels of hemoglobin and hematocrit should be maintained
>10 and >30, respectively. Furthermore, intake should be within 500 cc output in order to avoid preload increase and heart failure. In case of rapid change of symptoms
and/or hemodynamic instability, cardiologist consult along with ECG, biomarkers testing
(namely natriuretic peptides and troponin) and FoCUS exam is warranted to ascertain
potential cardiovascular causes and rapidly implement appropriate diagnostic-therapeutic
strategies [3,4].
9. Conclusions
MACEs are common causes of perioperative mortality and major morbidity. Minimizing these complications requires a careful preoperative integrated multidisciplinary
assessment including definition of surgical risk per se and related timing exclusion of
clinical unstable conditions or recent coronary revascularization estimation of functional
capacity and overall cardiovascular perioperative risk (Figure 1). The implementation of
cardiovascular non-invasive/invasive tests and therapeutic interventions are dependent on
patient and surgery specific characteristics (personalized medicine model). Finally, during
the COVID-19 pandemic, careful attention should be paid to minimize the risk of infection
transmission when performing cardiac consultation.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcdd8100126/s1, Table S1: Classification of elective surgical interventions according to the
surgical risk of the procedures, Table S2: Classification of elective surgical interventions according to
bleeding risk of surgical and anesthesiologic procedures.
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Abbreviations
AF
ARBs
ASA
BMS
BNP
CA
CABG
CAD
CCTA
CMRI
COVID-19
ClCr
CT
DAPT
DES
ECG
FoCUS
GFR
GPIIb-IIIa
HF
INR
LMWH
MACEs
METs
MI
NOACs
NSQIP
NT-proBNP
PCI
RCRI
SARS-CoV-2
SPECT
TTE
TURP
UFH
VKAs

atrial fibrillation
angiotensin receptor blockers
aspirin
bare metal stent
brain natriuretic peptide
coronary angiography
coronary artery bypass grafting
coronary artery disease
coronary computed tomographic angiography
cardiac magnetic resonance imaging
2019 Coronavirus disease
creatinine clearance
computed tomography
dual antiplatelet therapy
drug eluting stent
electrocardiogram
focused cardiac ultrasound study
glomerular filtration rate
glycoprotein IIb/IIIa inhibitors
heart failure
international normalized ratio
low molecular weight heparin
major adverse cardiac events
metabolic equivalents
myocardial infarction
non-vitamin K antagonist oral anticoagulants
National Surgical Quality Improvement Program
N-terminal-pro hormone BNP
percutaneous coronary intervention
Revised Cardiac Risk Index
severe acute respiratory syndrome coronavirus-2
single-photon emission computed tomography
transthoracic color-Doppler echocardiography
transurethral resection of the prostate
unfractionated heparin
vitamin K antagonists
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